Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus abatacept in biologic-inadequate response rheumatoid arthritis
NL-OMON53110Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2018
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib and abatacept in rheumatoid arthritis (RA) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline in DAS28 (CRP). Started Feb 2018; status: completed.
02
Drugs
upadacitinibabatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON53110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53110.